EastGate Pharmaceutical Token (EGP)

EastGate Pharmaceutical Token (EGP)

Created using Figma
EastGate Pharmaceutical Token (EGP). Creating solutions to vital pharmaceutical problems by merging pharmacy with blockchain. EGP Token would be used to make payments in pharmaceutical stores across the world.
데이터를 사용할 수 없습니다.
2023. 6. 1.
2023. 7. 31.
100% 완료된
기금 모금 - 데이터 없음
150 000.00
단단한 모자 10 000 000.00
past
토큰 세부 정보
증권 시세 표시기
EGP
총 공급
100,000,000,000
토큰 배포
Token Sale Program - 60%
Reserve Fund - 8%
Team and Founders - 15%
Board Advisors - 4%
Ecosystem Development - 7%
Marketing and Bounty - 6%
Funds allocation:
Engineering and Development - 40%
Business Development - 12%
Marketing & Promotion - 20%
Legal & Regulation - 10%
Operational & Administration - 8%
Contingency - 4%
Partners - 6%
허용 된 통화
ETH, BTC, BCH, BNB, USDT, DOGE, XRP, TRX
최소 기부금
0.01
USDT
추가 세부 사항
카테고리
암호 해독 성, 건강, 지불

약 EastGate Pharmaceutical Token (EGP)

EastGate Biotech Corp. is a dynamic biotech company concentrating on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. We are developing a technology platform for enhanced drug delivery designed to provide alternative administration of known drugs with the goal of offering patient-friendly products to improve compliance and increase health benefits to fit today's health-conscious lifestyles. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution based on proprietary composition, but we believe that our technology may also be applicable to the delivery of other active pharmaceutical ingredients. We may also develop other novel formulations of pharmaceutical and natural products. The company has identified several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions.

The company will focus on validating its delivery technology platform and determining different applications for expanding therapeutic treatments. The company intends to out-license different applications. We have not entered into any definitive agreements with respect to the foregoing and there is no guarantee that the Company will enter into such agreements on favorable terms or at all.

Our secondary goal is to leverage our technology for the oral delivery of other active pharmaceutical ingredients for the treatment of non-diabetes indications. If we are successful in obtaining regulatory approval, we may also out-license our intellectual property to other pharmaceutical companies.

% name % 로드맵

  • March 2022

  • Start of the ERC20 Crypto Platform Development
  • April 2022

  • Start of the Preparation for the ERC20 Token Testing
  • August 2022

  • Deployed Our ERC20 Token (EGP) Over Main Network
  • February 2023

  • Presale Starts
  • 더 읽기
  • April 2023

  • Presale Ends
  • May 2023

  • Listing on 2 CEX platforms
  • November 2023

  • Collaboration with top pharmaceutical stores across the world to accept EGP token as payment in stores for pharmaceutical services and items
  • July 2024

  • Training of 10,000 pharmacists to make positive impact in the health field
  • September 2024

  • Launch of EastGate blockchain

EastGate Pharmaceutical Token (EGP) 팀

검증 됨 0%

주의. 확인되지 않은 회원은 실제로 팀원이 아닌 위험이 있습니다.

Rose Perri
Chief Executive Officer
확인되지 않음
Bill Abajian
Chairman, President and Chief Operating Officer
확인되지 않음
Anna Gluskin
Chairman Emeritus
확인되지 않음

EastGate Pharmaceutical Token (EGP) 최근 뉴스

  • 정보 업데이트에는 시간차가있을 수 있으므로 각 ICO 프로젝트에 대한 정확한 정보는 공식 웹 사이트 또는 기타 커뮤니케이션 채널을 통해 확인해야합니다.
  • 이 정보는 ICO 기금 투자에 대한 제안이나 조언이 아닙니다. 관련 정보를 철저히 조사하고 ICO 참여를 결정하십시오.
  • 이 콘텐츠에 대해 수정해야 할 문제 또는 문제가 있다고 생각되거나 자신의 ICO 프로젝트를 제출하고자 할 경우 이메일을 보내주십시오. a>
면책 조항 및 위험 경고를 읽으십시오. 면책 조항 및 위험 경고 표시.